SCHEMBL14689869

SCHEMBL14689869

O=C1CCC=C1c1ccc(O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 2/20 0.42
ESR2 Q92731 3/20 0.40
ESR1 P03372 2/20 0.40
MGAM O43451 1/20 0.39
GAA P10253 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
SENP1 Q9P0U3 1/20 0.39
BACE1 P56817 2/20 0.38
PTPN1 P18031 1/20 0.38
QDPR P09417 2/20 0.37
MMP3 P08254 1/20 0.34
BCL2L1 Q07817 1/20 0.34
KMT2A Q03164 2/20 0.34
PBRM1 Q86U86 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4198220 0.79 SIGMAR1 (0.37) GAACYP1A2MAPT
SCHEMBL5215863 0.79 CYP3A4 (0.43) BCL2L1CYP3A4USP2MAPT
SCHEMBL11133453 0.78 BACE1 (0.41) GAABACE1PTPN1KMT2ACYP1A2
SCHEMBL18088752 0.75 BACE1 (0.47) BACE1CYP1A2
SCHEMBL2721721 0.75 BACE1 (0.53) ESR2BACE1PTPN1KMT2AMEN1
SCHEMBL8405010 0.72 QDPR (0.56) ESR2ESR1QDPRMMP3BCL2L1
SCHEMBL12220592 0.71 HSD17B1 (0.42) HSD17B1ESR2ESR1MGAMGAA
SCHEMBL12263266 0.68 ALDH1A1 (0.42) GAABCL2L1TP53MAPTRAB9A
SCHEMBL5791186 0.68 BRD4 (0.41) GAAKMT2ACYP1A2CYP2C9MEN1
Phenylacetylene SCHEMBL8708498 0.67 CYP1A2 (0.33) BACE1CYP1A2CYP2C9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130040935-A1 CYCLIC KETO-ENOLS FOR THERAPY BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040935-A1 CYCLIC KETO-ENOLS FOR THERAPY AKR1B1, AKR1C3, AKR1A1 HSD17B1 36/4885ESR2 169/4885ESR1 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.